To investigate the correlation between thyroid-stimulating hormone (TSH), free T3 (FT3), free T4 (FT4), thyroid-stimulating hormone receptor antibody (TRAb), and pathological parameters of ovarian cancer, we selected 122 patients with ovarian cancer and 70 patients with benign ovarian tumor. The differences in the positive rates of different pathological parameters, including TSH, FT3, FT4, and TRAb, in their serum were detected and compared through highly sensitive electrochemical immunoassay. We found that the positive rates of TSH, FT3, FT4, and TRAb in serous cystadenocarcinoma were higher than those of mucinous cystadenocarcinoma and other types of ovarian cancer. Meanwhile, the positive rates of FT3 and FT4 in stage III and IV ovarian cancer were lower than those in stage I and II ovarian cancer. However, the positive rates of FT3 and FT4 in poorly differentiated ovarian cancer were higher than those in moderately differentiated and well-differentiated ovarian cancer. The serum levels of TSH, FT3, FT4, and TRAb preoperatively, postoperatively, and after four cycles of ovarian cancer were significantly different from those in the control group. Thus, we conclude that TSH, FT3, FT4, and TRAb were abnormally expressed in the serum of ovarian cancer patients. And the application of highly sensitive electrochemical immunoassay for the detection of TSH, FT3, FT4, and TRAb in serum has important clinical value in the diagnosis of ovarian cancer.
Clinical evaluation of highly sensitive thyroid stimulating hormone immunoradiometric assay (RIABEAD II) kit.
